Xenon Pharmaceuticals Inc. (XENE) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $37.41 (-0.35% 1D, market cap $3.64B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, XENE ranks #601 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XENE carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OGN (Organon & Co.) holds a B- grade (70/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B) and AMLX (Amylyx Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.60B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).
Per XENE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001582313), Xenon Pharmaceuticals Inc. generated $0 in revenue, -$345.9M in net income, and -$279.9M in free cash flow against $633.2M in total assets and $23.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While XENE currently carries a cautious 37/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($44.42) and Max Pain ($39.28) forces dealer call-delta covering toward $76.29.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Xenon Pharmaceuticals Inc. (XENE) slipped -0.35% to $37.41, trading at 10% of its 52-week range ($33.38 – $72.66). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
www.debelegger.nl report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
VANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercia
XEN1701 achieved target profile, including desired NaV1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic cardiovascular effectsXEN1120 ach
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +7.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XENE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XENE. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Xenon Pharmaceuticals Inc. (XENE) ranks #601 by composite RQD confidence (37/100, grade D-) and #190 by equity capitalization ($3.64B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with XENE at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XENE
ACTIVE
Xenon Pharmaceuticals Inc. | D- | 37/100 | — | — | -35.0% | -0.35% | $3.64B | Benchmark Subject |
| OGN Organon & Co. | B- | 70/100 | 19.4x | 53.3% | 24.9% | +0.22% | $3.63B | /ogn-vs-xene → |
| AMLX Amylyx Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | +0.63% | $3.60B | /amlx-vs-xene → |
| IRON Disc Medicine Inc. | D+ | 54/100 | — | — | -27.5% | -2.41% | $3.68B | /iron-vs-xene → |
| ACAD ACADIA Pharmaceuticals Inc. | D | 50/100 | 9.1x | 91.7% | 7.9% | -0.82% | $3.58B | /acad-vs-xene → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xenon Pharmaceuticals Inc. (XENE) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$345.9M, operating cash flow of -$279.1M, and free cash flow of -$279.9M (-51.7% YoY). On the balance sheet, XENE closed FY2025 with $633.2M in total assets against $23.1M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$345.9M | -$279.1M | -$279.9M | $633.2M | $23.1M |
| FY2024 (FY) | 2024-12-31 | $0 | -$234.3M | -$181.4M | -$184.5M | $798.1M | $19.5M |
| FY2023 (FY) | 2023-12-31 | $0 | -$182.4M | -$151.1M | -$151.1M | $2.00B | $467.9M |
As of 2026-11-02, Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $37.41 (-0.35% 1D, market cap $3.64B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, XENE ranks #601 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XENE carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OGN (Organon & Co.) holds a B- grade (70/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B) and AMLX (Amylyx Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.60B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).
Per XENE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001582313), Xenon Pharmaceuticals Inc. generated $0 in revenue, -$345.9M in net income, and -$279.9M in free cash flow against $633.2M in total assets and $23.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
XENE last traded at $37.41 (-0.35% on volume of 1,119,068 shares), positioning the stock -15.78% below its 50-day simple moving average ($44.42) and -28.53% below its 200-day simple moving average ($52.34). Across its 52-week range of $33.38 to $72.66, XENE sits at the 10.3% percentile with a 14-day RSI of 44.9 (NEUTRAL RANGE) and an implied next-earnings move of ±7.1% ($34.75 to $40.07).
Why XENE Stock slipped -0.35% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, XENE scores 37 out of 100 and carries a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
Investor implications: the rating points to a company with low financial leverage but deeply negative operating economics. Upside depends on a sustained shift toward cash generation; the valuation tradeoff is that a forward P/E of 29 (per market data) prices in expectations the trailing numbers do not yet show. This is an analytical framing, not personalized advice.
Xenon Pharmaceuticals Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, its market capitalization is $3.6B. The source data does not describe its products, customers, or revenue model. Reported revenue for FY 2025 is $0.0M, so the company does not currently generate revenue in the reported periods.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-373.1M | $-345.9M | N/A | $-279.9M | $199.2M | $23.1M |
| FY 2024 | $0.0M | $-279.3M | $-234.3M | N/A | $-184.5M | $142.7M | $19.5M |
| FY 2023 | $0.0M | $-214.1M | $-182.4M | N/A | $-151.1M | N/A | $467.9M |
Per the SEC financials, losses widened each year across the three periods, with FY 2025 operating income of $-373.1M. Gross margin is 0%, operating margin is -36.7%, and net margin is -34% per market data, with ROIC at -35%. Per the RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 5/9. Cash rose from $142.7M to $199.2M while debt declined from $467.9M (FY 2023) to $23.1M (FY 2025), indicating a strengthened balance sheet despite continued cash burn.
Six news items reference XENE, all tagged YELLOW under the MARKET WIRE impact label. Headlines are generic market-coverage pieces (Yahoo Finance, Benzinga, Stock Titan, and others) describing price action, institutional positioning, and fundamental catalysts without specific event detail. Benzinga's item references a Q2 2026 earnings call transcript. Stock Titan reports that nine new employees received options to buy shares at $37.54 each. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded. Risk watch items: negative earnings, ongoing cash burn, and the stock sitting in the lower portion of its 52-week range.
Per the Butterfly Supply-Chain Graph, supply chain is recorded as NONE, with no butterfly links. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. An investor should note that the absence of recorded links is a data gap, not evidence of independence.
Real-time company headlines, analyst actions, and sector developments for Xenon Pharmaceuticals Inc. (XENE) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
www.debelegger.nl report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Xenon Pharmaceuticals Inc. (XENE) market action, institutional positioning, and fundamental catalysts.
Welcome to the XENE (Xenon Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on XENE, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Xenon Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on XENE, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $37.54 (52-wk range $33.38 - $72.66), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).